
DrugDev looks to Lilly for chairman role
pharmafile | June 15, 2015 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | drugdev, jeffrey kasher, lilly
Dr Jeffrey Kasher has joined US healthcare tech firm DrugDev as the chairman of its advisory board.
Kasher takes 28 years of experience working at Eli Lilly to the clinical research team that offers tech solutions to help sponsors, CROs and sites to do more trials.
In 2013 CenterWatch named Kasher one of the “20 Innovators Changing the Face of the Clinical Trials Industry”.
“Jeff Kasher doesn’t work in clinical research innovation, he is clinical research innovation – and we couldn’t be more proud to have the man who essentially defined the term advising us on how to make the maximum impact on the way people run clinical trials,” says Ibraheem Mahmood, president and chief executive of DrugDev.
“The only negative thing I can say about Jeff, especially coming from a company devoted to achieving wellness, is he makes us all look bad by competing in Iron Man competitions and running marathons,” Mahmood adds.
Related Content
NICE RECOMMENDS LILLY’S TIRZEPATIDE (MOUNJARO ®▼) FOR MANAGING OVERWEIGHT AND OBESITY IN FINAL DRAFT GUIDANCE
BASINGSTOKE, 5th December 2024 – Eli Lilly and Company announced today that the National Institute …

Lilly’s COVID-19 drug has EUA revoked in favour of combination therapy
The FDA have revoked Emergency Use Authorization (EUA) of Eli Lilly’s bamlanivimab drug for the …

Lilly’s ulcerative colitis treatment meets all key endpoints in Phase III trial
Eli Lilly’s mirikizumab treatment for ulcerative colitis (UC) patients has met the primary endpoints and …






